cystic-fibrosis

Gilead Sciences, Inc. (Nasdaq: GILD) announced on Tuesday that the U.S. Food and Drug Administration has approved Cayston, an inhaled treatment for respiratory symptoms in cystic-fibrosis patients with pseudomonas aeruginosa, for marketing. Cayston, with the generic name of aztreonam, was approved...